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Abstract 
The development of ivermectin as a complementary vector control tool will require good quality evidence. This paper 
reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be use-
ful. Potential scenarios and pharmacological strategies are compared in order to help guide trial design. The rationale 
for a particular timing of an ivermectin-based tool and some potentially useful outcome measures are suggested.
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Background
Vector control with long-lasting insecticidal nets (LLINs) 
or indoor residual spraying (IRS) is the one of major 
underlying reasons for the decline in malaria prevalence 
seen in the last 15 years [1]. Yet although currently avail-
able vector control tools can strongly reduce malaria 
transmission, reaching and sustain cero transmission is 
unlikely without innovation [2]; particularly in presence 
of Insecticide resistance [3] and residual malaria trans-
mission [4].
Endectocides are systemic drugs that kill blood-feeding 
arthropods as well as internal parasites. They have been 
used in the veterinary market for more than 30 years. Of 
these, ivermectin was the first-in-class drug [5]. Since 
the 1980’s, ivermectin is used in humans for the treat-
ment of onchocerciasis and lymphatic filariasis. Mass-
administration of ivermectin could complement vector 
control with LLINs and IRS by reaching vectors that bite 
in unprotected temporal/spatial gaps or are resistant to 
insecticides.
As a potential new paradigm, early development should 
be guided by the results of semi-field or small-scale trials 
that could justify investment in large-scale field trials [6]. 
This paper provides a comprehensive assessment of the 
concepts that can influence the design of studies evaluat-
ing this potential new tool.
A not‑so‑trivial question: transmission‑blocking or vector 
control?
The term transmission-blocking drug refers to drugs 
that impede the transmission of the malaria parasite 
from humans to mosquitoes by killing gametocytes or 
inhibit the development of sporozoites in the mosquito 
[7]. Low-dose primaquine is recommended by World 
Health Organization (WHO) to all patients with parasi-
tologically-confirmed Plasmodium falciparum malaria 
in order to block transmission from infected humans to 
mosquitoes [8]. Although there is guidance for potential 
development [9], there is currently no molecule in use to 
specifically inhibit parasite development in the mosquito.
If used at the appropriate dose and spacing, mass drug 
administration (MDA) with ivermectin could reduce 
malaria transmission, due mainly from the death of mos-
quitoes that feed on treated subjects [10, 11]. Additional 
benefit could result from reduced mosquito fitness and 
fertility [12–14], a shift in the mosquito population age 
structure towards younger females [11] and possibly, to 
a considerably lesser extent, by partial sporogony inhibi-
tion [15, 16] and a potential inhibition of hepatic schiz-
onts [17]. Yet the impact on vectorial capacity would be 
driven mainly by a reduction of the daily probability of 
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mosquito survival [18] as it is with LLINs and IRS, with 
the additional advantage of targeting the mosquitoes 
that bite outside protected environments and times (see 
“Residual transmission” below).
Ivermectin MDA would constitute a new paradigm 
for vector control and reducing transmission accord-
ing to the criteria of the Vector Control Advisory Group 
(VCAG) on new tools [19] as it would:
(i)  Offer indirect human protection by reducing local 
transmission (like indoor residual spraying does).
(ii) Have activity against different species of mosqui-
toes.
(iii) Work in the context of insecticide resistance, since 
the mechanism of action is different (glutamate-
gated chlorine channels).
(iv) And cannot be described appropriately by an exist-
ing target product profile.
Defining the ideal context for ivermectin use for malaria 
control
Ivermectin is not envisioned as a stand-alone tool. 
Any ivermectin-based intervention should be tested 
and deployed in conjunction with other WHO-recom-
mended malaria control measures, including effective 
case management, vector control measures and drug-
based prophylactic schemes in settings and groups appli-
cable, such as SMC and IPTp. Ultimately, additional 
studies will be required to streamline the malaria control 
toolbox.
Four situations are defined for which an ivermectin-
based tool could be a particularly valuable addition to 
current interventions.
Residual transmission
Residual transmission (RT) is defined as the transmis-
sion that persists after universal coverage with effective 
LLINs and/or IRS to which the local vectors are fully 
susceptible [4, 20–22]. It is the consequence of mosquito 
behaviour that defines the limits of what is achievable 
with these interventions and includes outdoor and early 
biting, outdoor resting, behavioural avoidance and feed-
ing upon animals, as well as human behavioural factors 
(failure to utilize LLINs, outdoor sleeping). In this con-
text, prolonged and appropriate coverage with LLINs/IRS 
can drive transmission to very low levels, but it is unlikely 
to interrupt transmission in some settings as the pro-
portion of residual likely to increase progressively. RT is 
deemed as a significant challenge to malaria elimination 
which requires new or improved vector control methods 
or systems [4]. The development of new tools to address 
RT has been recognized as a priority by the WHO Global 
Malaria Programme [21].
Ivermectin distributed at population level would tar-
get mosquitoes feeding on treated subjects, regardless of 
the place or time of the blood meal, effectively targeting 
residual transmission.
Of note, one of the behavioural adaptations leading to 
residual transmission is a shift to feeding on animals [4, 
20]; this could have implications for the use of ivermectin 
at the community level because untreated peridomestic 
animals would allow for this escape mechanism [23, 24], 
even after high human coverage. Ivermectin treatment of 
significant primary blood sources available to mosquitoes 
should be considered [25].
Figure  1 is a schematic illustration (not at scale) of 
the temporal, spatial and blood sources gaps typically 
left uncovered by LLINs and IRS as a source of residual 
transmission.
Insecticide resistance
In 2012, when the Global Plan for Insecticide Resistance 
Management in malaria vectors was launched, resistant 
Anopheles had been identified in 64 malaria endemic 
countries, representing all WHO regions [26]. Of particu-
lar concern was the presence of resistance to all classes 
of insecticides in some areas and the appearance of high 
intensity of resistance up to 1000-fold known levels [27]. 
The presence of resistance to pyrethroids, the only insec-
ticide used in LLINs, particularly in sub-Saharan Africa 
has worsened over the last 3 years [28], although the pub-
lic health impact is still being debated [29]. Insecticide 
resistance is considered an important challenge for the 
sustainment of the achievements in malaria control over 
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Fig. 1 Temporal, spatial and blood-source gaps as a cause of residual 
malaria transmission. The gaps are not at scale. New interventions are 
needed to cover these gaps
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the last decade [1]. In this context, new strategies with 
novel mechanism of actions may be particularly valuable.
Ivermectin’s mechanism of action differs from all four 
classes of insecticides used today. Furthermore, a study 
done with Anopheles coluzzi carrying the kdr muta-
tion associated with pyrethroid resistance showed they 
remained susceptible to ivermectin [30].
Ivermectin itself is not exempt of the theoretical pos-
sibility of resistance and should it be deployed for malaria 
vector control, there will be a need to monitor for the 
eventual appearance of resistance. Different isoforms 
of the glutamate-gated chlorine channels have been 
described in Anopheles gambiae, at least one of them is 
insensitive to the drug. The selective over-expression of 
this isoform could be a mechanism for ivermectin resist-
ance [31]. To date, there are no reports of this occur-
ring in the field. Additionally, ivermectin is a substrate 
of cytochrome  P450 3A4 [32] and to efflux pumps such 
as the P-glycoprotein [33], in the absence of fitness cost, 
overexpression of these enzymes/proteins could theoreti-
cally offer protection from ivermectin.
There is need for studies assessing the potential syner-
gism of sub-lethal ivermectin doses on the susceptibility 
of mosquitoes to public health insecticides. This is based 
on proven reduced fitness after exposure to sub-lethal 
ivermectin doses [12, 34].
High transmission settings
The high vectorial capacity observed in sub-Saharan 
Africa has been identified as an important challenge 
to elimination [2, 35]. A baseline of high transmission 
decreases the technical and operational feasibility to 
achieve and maintain elimination, ultimately affecting the 
financial feasibility [36]. New paradigms in vector con-
trols are needed to achieve and sustain markedly reduced 
transmission on the path to elimination in said areas.
Elimination settings
Any ivermectin based tool is expected to have a relatively 
short effect (weeks, rather than months or years), even 
with the hypothetical use of long-lasting formulations. 
Therefore, ivermectin’s profile fits well in the context of 
intense, time-limited efforts aimed at elimination. This 
could also limit the risk of resistance to the molecule.
Additional factors
Additional factors that could help select the most appro-
priate setting for proof-of-concept studies include:
•  The presence of artemisinin resistance
The threat of artemisinin resistance spreading out 
of the greater Mekong subregion has created a sense of 
urgency given the current lack of other anti-malarials 
with the same efficacy and safety as artemisinin. The 
outdoor-biting behaviour of the local vectors makes iver-
mectin an attractive additional tool for local elimination.
•  The specific susceptibility of the local vectors to iver-
mectin
Preliminary data suggest that different species of 
malaria vectors can have different susceptibility to iver-
mectin [37]. The dominant species in particular regions 
and their sensitivity to the drug should be taken into 
account when defining the target dose and scheme.
•  The local transmission pattern
The local seasonality can greatly influence the efficacy 
of pulsed interventions on the basic reproductive number 
such as IRS or MDA with ACTs (this is partly depend-
ent on the duration of effect) [38]. The main question 
deriving from this point is: when would be the best time 
to use/test an ivermectin-based tool? A partial answer is 
given below. Modelling is a key tool in the formulation of 
testable hypotheses in the context of other available data.
Selecting the right proof‑of‑concept scenario: where is it 
testable?
The following concepts apply to ivermectin as a test-
able proof-of-concept requiring a change of label; for 
any other candidate endectocides the regulatory frame-
work would need licensure of a new product. Selecting 
the appropriate scenario to prove the concept is a key 
point and for this, baseline epidemiology and baseline 
transmission measures must be taken into account. High 
transmission settings could shorten testing time while 
low transmission settings can be a financial challenge for 
initial studies due to larger sample size; but the implica-
tion of each will be different (reducing transmission vs 
driving to zero). Key outcome indicators should reflect 
transmission e.g. entomological inoculation rate (EIR) 
and/or incidence.
Six scenarios for the use of an ivermectin-based tool 
are proposed here using the criteria described above. In 
all cases, it is understood that ivermectin would be used 
as a complementary tool to core vector control measures 
and any other strategy used for an elimination/control 
campaign. All scenarios proposed here are envisaged as 
points in an elimination continuum and all assume an 
ivermectin campaign and community administration, 
regardless where in the continuum it is administered. 
Table 1 is just an example of how these scenarios could 
be ranked based on the criteria described in the previous 
section.
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Elimination in the Greater Mekong Sub‑region
The outdoor and early biting behaviour of the local vec-
tors and the urgency created by artemisinin resistance 
support the use of novel tools in elimination efforts in 
this region. The local low levels of transmission raise 
the important question of whether a large enough sam-
ple size can be included to make the potential effect 
measurable.
Elimination in selected areas of countries with a 
heterogeneous transmission
In the face of high national burden of disease and threat 
of insecticide resistance, a complementary novel tool 
like ivermectin could help accelerate towards local [39] 
or sub-regional [40] malaria reduction or elimination 
targets.
Reduce disease burden in areas of high vectorial capacity
The effect of a single ivermectin intervention would only 
last for a few days to weeks depending on the dosing regi-
men and formulation used. This additional tool however, 
even if short-lasting, might serve as a complement to 
further reduce transmission and achieve consolidation 
in the context of elimination campaigns with multiple 
interventions.
Stem insecticide resistance in well‑defined areas with high 
resistance intensity
In areas with resistance to multiple insecticides or with 
high insecticide resistance intensity, periodic deployment 
of an ivermectin-based tool could help suppress the 
resistant vector population while novel insecticides 
are introduced or elimination is assessed. This could be 
assessed by periodic evaluation of insecticide resistance 
markers. Of note, this would not be a regulatory end-
point for licensure.
Elimination from hotspots in the endgame
In the context of elimination efforts, modelling predicts 
that human-to-mosquito transmission efficiency will 
increase as malaria is controlled [41], also resistance may 
potentially concentrate in any hotspots left [42]. Ivermec-
tin could be an additional tool in last mile focal efforts.
Control of outbreaks
Given its short duration, an ivermectin-based tool could 
prove useful when a quick, short-lasting suppression of 
the vectorial capacity is needed.
Selecting ivermectin‑based strategies for malaria control: 
factors affecting the potential impact
Ivermectin is expected to reduce the (EIR) by an amount 
that is influenced by:
The plasma levels reached as a factor of the  LC50
The lethal concentration 50  (LC50) is the concentration 
of ivermectin in the imbibed solution or blood meal that 
kills 50% of the mosquitoes during a defined period of 
observation [43]. Although not usually reported that way, 
it should always include the timeframe i.e. 3-day-LC50 
Table 1 This is an example of how the potential scenarios for a proof-of-concept study could be considered
Testable refers to the potential implications of the transmission pattern on sample size and the feasibility of controlled clinical trials for each particular scenario
GMS Greater Mekong Subregion
Residual trans‑
mission
Insecticide resist‑
ance
Transmission Targeted 
for elimination
Artemisinin 
resistance
Burden 
of malaria
Testable
Elimination in the 
GMS
+++ + + +++ +++ + Possibly
Elimination in 
selected areas 
of sub-Saharan 
Africa
++ +++ +++ +++ – +++ Yes
Reduce disease 
burden in high-
transmission 
areas
+ Any +++ + +++ Yes
Stem insecticide 
resistance in 
well-defined 
areas
Any ++++ Any + Any + Difficult
Elimination from 
hotspots in the 
endgame
++ +++ +++ +++ Any +++ (local) Doubtful
Stem of outbreaks + Any ++ Any Any + Doubtful
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versus 10-day-LC50. The vector lethality caused by iver-
mectin is dose-dependent. As plasma levels increase and 
mosquitoes imbibe higher concentrations in bloodmeals, 
the time to reach 50% mosquito mortality will be shorter. 
Once plasma levels close to the 3-day-LC99 of a particu-
lar vector species are reached on an individual, almost 
all Anopheles from that species feeding on that particu-
lar individual will die before completing the gonotrophic 
cycle. This effect will be seen as long as said levels are 
sustained.
The duration of effective mosquitocidal concentrations
The direct mosquitocidal effect can only take place as 
long as the drug is present in the blood at effective con-
centrations [44], for Anopheles the 10-day-LC50 ranges 
from as low as 6  ng/ml for Anopheles gambiae [45] to 
36  ng/ml for Anopheles darlingi [46] or 47  ng/ml for 
Anopheles aquasalis [47] (the former two represent 
5-day-LC50). The duration of the mosquitocidal concen-
tration will be in close relationship with the particular 
ivermectin susceptibility of the local vectors, it is yet to 
be assessed whether this could be related to metabolic 
resistance to other insecticides.
The relationship between plasma levels above the kill-
ing threshold and duration is likely to be nonlinear and 
possibly related to the area under the pharmacokinetic 
curve, but additional modelling work will be needed to 
prove this. Both parameters will be in direct relation-
ship with the dose per body weight used and the num-
ber/spacing of the doses. The proposed process to design 
a trial will be to first define the target values of these 
parameters using modelling in order to choose the dose 
per body weight and scheme to be tested.
The population coverage
Modelling shows that a mass screening and treatment 
(MSAT) approach to ivermectin would have little effect 
on transmission. The real value of this tool would be in 
the context of community-based treatment. Modelling 
also points to higher coverage as an important driver of 
the potential impact of an ivermectin-based tool [44]. In 
other words, even if an MSAT strategy is used to treat the 
parasite, ivermectin would only have a relevant effect if 
given to as many eligible individuals as possible, regard-
less of RDT results.
The proportion of vectors feeding on alternative blood 
sources
Primarily zoophilic mosquitoes can sustain endemic 
malaria transmission even if they feed only rarely upon 
humans [4]. Untreated peridomestic animals could the-
oretically sustain mosquito populations even when all 
humans are ivermectin-treated. This could be a reason to 
consider including cattle and other peridomestic animals 
in endectocide-based strategies [25, 48], but this would 
require field data, both on the importance of these ani-
mals as an important source of nutrition, as well as the 
impact of treating them with ivermectin.
The magnitude and duration of beneficial sublethal effects 
of the drug on the mosquitoes
Mosquitos feeding at sublethal ivermectin concentrations 
are likely to experience reduced fertility, to fall temporar-
ily to the floor, unable to fly (knock down) and to show 
incoordination while flying, all of which can contribute 
to additional vector mortality and reducing transmission 
of vector-borne diseases [12–14]. The relevance of these 
effects for entomological or epidemiological impact is 
still unclear.
Figure  2 schematically illustrates how the concepts of 
plasma levels reached, duration of said levels and cover-
age of blood sources combine to determine the theoreti-
cal magnitude of effect of ivermectin MDA for malaria 
control.
Selecting ivermectin‑based strategies for malaria control: 
how to use it?
Using the current oral formulation
The current oral formulation is used for onchocerciasis at 
the 150–200 µg/kg/dose with a frequency of one to four 
times a year in different settings, but killing mosquitoes 
was not the intended outcome of this regimen, and until 
recently there were no data on the entomological impact 
of this large-scale use. There is now evidence that iver-
mectin MDA at this dose can reduce the 3-day survival 
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Fig. 2 The theoretical efficacy of ivermectin mass drug administra-
tion based on three key parameters. Effective plasma levels would 
be directly linked to the specific ivermectin susceptibility of the local 
vectors. RME reduce metabolism or elimination e.g. using drugs
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of mosquitoes caught in the area for up to 1 week after 
MDA [49, 50]. This results in the age structure of the 
mosquito population being shifted towards younger, less 
infectious ages for up to 3 weeks and a significant reduc-
tion of the sporozoite rate to levels as low as 20% of the 
pre-MDA ones for 2 weeks [49, 51].
Considerations for using the current formulation at 
the onchocerciasis-approved doses should be based on 
the clear determination of the susceptibility  (LC50) of the 
main local vector species and the modelled impact of dif-
ferent doses and schemes. The results of recently finished 
trials could help to further parametrize the models [52, 
53]. Doses of 200  mcg/kg repeated every 3  weeks can 
have a measurable impact on malaria incidence but this 
implies a intense logistical efforts [54]. Data are emerging 
on a variety of options, and the final regimen will need to 
balance biological impact and operational feasibility.
Finally, the current oral formulation could be used, in a 
clinical trial context, at different doses and frequency to 
provide “proof of concept” that ivermectin delivered for 
a specified number of days via MDA program would have 
a measurable public health and mosquito outcome, this 
can guide the development of novel formulations.
Potential novel formulations
Modified formulations have been used in animal studies 
as a way to deliver stable mosquitocidal concentrations of 
ivermectin for longer periods of time (ranging from 7 to 
>30 ng/ml) [55–57] from 2 to 24 weeks. Using the exist-
ing formulation can prove the concept, but whether that 
multiple-dose regimen is deliverable at scale will define 
whether a new formulation with different performance 
characteristics would be optimal.
Target coverage
The target coverage will be defined with help from mod-
elling; key points will be the exclusion of certain groups 
(children, pregnant or potentially pregnant women due 
to the lack of safety data of higher or more frequent 
doses) and the demographic characteristics of the popu-
lation. The importance of alternative blood sources from 
peridomestic animals and their potential role in sustain-
ing mosquito populations should be contemplated when 
defining the biological coverage of an ivermectin-based 
intervention [25, 48].
Panel A in Fig.  3 illustrates the different scenarios 
in which ivermectin could be used in animals or peri-
domestic animals according to vector behaviour as well 
as the potential comparative advantage of ivermectin 
over LLINs and IRS in some settings, panel B is adapted 
with permission from Killeen et  al. [58] and shows 
how ivermectin use could be tailored to the humans or 
livestock in different areas after the behaviour of the 
main local vectors.
Examples of possible use
The possibilities include using the current oral formula-
tion at different doses and spacing or developing a novel 
long-lasting formulation. In all cases, the use of ivermec-
tin would be in addition to core vector control tools with 
or without MDA to reduce the parasite pool at popula-
tion level.
Using the current oral formulation at high doses for a short 
period of time In this design, ivermectin is distributed at 
high doses (that is six to nine-fold the total dose approved 
for onchocerciasis distributed across several days) in 
order to increase the peak concentration in plasma and 
consequently the time above mosquitocidal concentra-
tions.
Using the current oral formulation at Onchocerca‑approved 
doses at intervals In this design, ivermectin is distributed 
at usual doses for a long time (200 mcg/kg every 3 weeks 
for months) to suppress the vector population or at inter-
vals aimed at modifying the age structure of the local vec-
tor populations.
Novel, slow release formulations of  ivermectin Devel-
oping novel, long-lasting formulations can increase the 
duration of the mosquitocidal effect after a single encoun-
ter [55, 56]. Injectable formulations seem to be the easier 
solution but could challenge implementation. Transder-
mal formulations may be acceptable to the population 
but require additional time and investment in R&D. The 
recently described ultra-slow release oral formulation by 
Bellinger et al. [56] is an elegant solution; it is capable to 
safely deliver mosquito-killing ivermectin concentrations 
for at least 2 weeks after a single dose and offers the pos-
sibility to combine several drug treatments at once [59].
The three envisioned possibilities are compared for 
potential advantages and disadvantages in Table  2. Of 
note, during clinical development it will be key to achieve 
equilibrium between efficacy (avoid too low doses) and 
safety (avoid too high doses).
Timing the intervention: when could ivermectin be most 
useful?
In many settings, malaria elimination programmes could 
resort to MDA campaigns to reduce the human reservoir 
[7, 60]. The timing of this intervention will be critical. 
It must be remembered however, that even after theo-
retical mass administration of these drugs with antici-
pated exclusions, a small but significant proportion of 
Page 7 of 13Chaccour and Rabinovich  Malar J  (2017) 16:166 
the parasite pool can survive in sporogonic stages in the 
mosquito [61]. Historically, the 1969–1976 Garki project 
pointed to the highest impact of MDA on transmission 
was seen during the dry season, when transmission was 
at its lowest and the parasite pool smaller [62] (this was 
based on parasite treatment, not endectocides).
It has been suggested that even after well-timed MDA 
parasite treatment campaigns, the proportion of para-
sites in the sporogonic stage in the mosquitoes, safe 
from the effects of drugs, can allow for transmission to 
continue after the dry season [61]. Figure  4 illustrates 
this concept.
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the coloured squares are used for illustration purposes as there are no clear limits for these scenarios. There are no “pure” scenarios in which mosqui-
toes bite only humans outdoors, so ivermectin should always be envisaged as a complementary measure. b shows how ivermectin use in a specific 
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Following this reasoning, the best moment to imple-
ment an ivermectin-based strategy would be prior to any 
parasite-reducing MDA; this could help reduce the mos-
quito to human transmission responsible for the “leap-
frog” pattern of transmission after MDA [61]. Additional 
modelling is needed in this aspect with the results of data 
of timing under various conditions. Final decisions on 
timing will need to take into account operational feasibil-
ity related to potential co-administrations and the influ-
ence of seasonality in accessing the communities.
Study design for a proof‑of concept of ivermectin MDA 
to achieve a measurable transmission reduction
Potential outcomes
Ivermectin MDA would be a transmission-reduction 
tool. As such, the best outcome measures would be 
directly related to transmission in humans and mosqui-
toes [63, 64]. The beneficial effect would be measured at 
community level. Outcome measures could be divided 
in epidemiological, entomological and laboratory-based. 
Efficacy measured through human endpoints will depend 
Table 2 Ranking different potential designs for ivermectin-based tools
ACT artemisinin combination therapies, MDA mass drug administration, SMC seasonal malaria chemoprophylaxis, R&D research and development
Regimen Efficacy Safety Acceptability Compliance Programmatic 
difficulty
R&D costs Implementation costs
High dose, single 
encounter
To be assessed To be assessed + +++ + + Similar to ACT MDA
Existing dose, multiple 
encounters
To be assessed + +++ + +++ + Similar to SMC
Novel long-lasting 
formulation, single 
encounter
To be assessed To be assessed To be assessed +++ + +++ Similar to SMC but high 
R&D costs and longer 
timeframe to avail-
ability
Human parasite
reservoir
Rainy season Dry season Rainy season
Purely 
sporogonic 
parasite 
populaon
Mosquito parasite
reservoir
Mosquito parasite 
reservoir
Human parasite 
reservoir
Theorecal 
100% 
effecve 
MDA
Fig. 4 The transmission between mosquito and human parasite pools. The parasite reservoir in the mosquito could allow for transmission to con-
tinue even after a fully effective MDA campaign. Adapted from Killeen 2013 [61]. The best timing for deployment of an ivermectin-based tool would 
be right before the red arrow and in combination with other vector control measures. MDA mass drug administration
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on baseline transmission intensity, requires robust base-
line data and is likely to vary across different transmission 
settings. The primary endpoint should show a tangible 
benefit for the population. The WHO-recommended pri-
mary efficacy endpoint for phases IIb and III of malaria 
vaccine trials is incidence of all episodes of malaria [65]. 
Case definition and case detection method must be 
clearly defined [65].
For transmission-blocking vaccines, it is suggested that 
entomological endpoints should fall into the category of 
secondary or exploratory endpoints [64]. However, in the 
case of ivermectin, the main effect is a reduction of trans-
mission achieved by killing an important proportion of the 
vector population, hence entomological endpoints need 
to be included among the primary outcome measures. Of 
note, EIR and related metrics are hard to measure reliably, 
operator dependent and can have substantial variation 
[66], alternative entomological endpoints could encompass 
variations on the mosquito population age structure and 
residual transmission. These are unlikely to suffice regula-
tory requirements but could be key intervening variables 
to explain the impact (or lack thereof) of the trial results.
Table  3 shows some examples of potential primary 
outcomes measures for clinical trials of ivermectin. See 
Tusting et al. [63] or Pinder et al. [64] for comprehensive 
reviews on measures of malaria transmission.
An important secondary analysis would be the effect 
of ivermectin on prevalence and intensity of NTDs and 
ectoparasites. In areas of co-endemicity, capturing these 
and other co-morbidities can help analyse the true 
impact of this potential tool.
Additional potential secondary outcomes include: the 
safety profile of the ivermectin regime, malaria incidence 
and transmission on the following season, cost-effective-
ness and community perception. A decision regarding 
endpoints needs to be made in consultation with regula-
tory agencies and informed by WHO.
Potential comparators
Any ivermectin-based tool needs to be used in an MDA 
campaign. The main question is: does ivermectin add 
value to existing intervention packages? this could be 
seen in terms of transmission, time to impact, costs or 
effectiveness.
Community standard core vector control interventions 
alone (LLINs/IRS vs LLINs/IRS + ivermectin) Using core 
vector control measures as comparator, without directly 
targeting the parasite with MDA would allow direct 
measurement of the impact of ivermectin in the presence 
of other vector control tools. This is likely to be needed 
whether ivermectin is envisaged as a target product or 
target partner drug for MDA. It may also have the benefit 
of the simplest study design and cost. This would be the 
simplest way of capturing the added value of ivermectin as 
a vector intervention and the referent for primary regula-
tory endpoint, to be discussed with regulatory agencies.
MDA with anti‑malarials (ACT MDA+LLINs+/−IRS 
vs ACT MDA +LLINs/+/−IRS + ivermectin) Current 
elimination strategies use ACTs that quickly clear parasi-
taemia, provide prophylactic effect and reduce carriage of 
immature gametocytes [67]. These campaigns are accom-
panied by vector control interventions as well as robust 
surveillance for case detection and treatment. Using these 
interventions as comparator with appropriate power 
would allow for the determination of any additional ben-
efit provided by a systemic insecticide like ivermectin to 
the leading hypothesis for accelerating elimination, par-
ticularly in Africa.
Transmission‑blocking interventions The only interven-
tion currently available is the use of primaquine to clear 
gametocytes. The effect of primaquine is primarily reduc-
ing the infectiousness of humans to mosquitoes. Iver-
mectin would primarily reduce vector density. Although 
both ultimately reduce transmission, a direct comparison 
would fail to acknowledge their very different mechanism 
of action and potential synergistic effect. Therefore, this is 
not the best approach, particularly for a regulatory end-
point.
Potential trial design
An individually-randomized clinical trial would fail to 
measure the expected community effect. Definitive proof 
of efficacy will arise from community or cluster rand-
omized trials. While there have to be enough clusters to 
meet tests for robustness given hypothesized effect size, 
and the specifics of the control intervention package 
may vary, there are, conceptually, some key elements to 
consider:
  • A vector control package representative of strategies 
and epidemiology for that region must be included.
  • Appropriate surveillance system for identification 
of cases and appropriate response systems must be 
in place. This includes reporting systems to ensure 
timely facility-based reporting.
  • The impact of ivermectin MDA is modelled to be 
proportionally higher in areas of high transmission 
[44, 56], giving a theoretical power advantage to that 
context, although trials under different scenarios 
(higher endemicity to accelerate the path to elimi-
nation and at low levels of endemicity to accelerate 
crashing transmission) have been considered and 
would be valuable in different context.
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Critical to trial design is the primary endpoint—as dis-
cussed above. Under the specific scenario of high ende-
micity, elimination strategy, cluster randomized MDA 
ivermectin, an illustrative endpoint would be the com-
munity impact (public health), with key secondary end-
points (transmission; cases).
Detailed discussion of trial design is beyond the scope 
of this document, the reader is referred to recent com-
prehensive reviews on the design of trials to assess vector 
control and transmission blocking tools [68, 69]. There 
are also potential ethical implications of trials assessing 
a drug that reduces transmission but does not provide a 
direct individual benefit. These issues has been particu-
larly discusses in the context of transmission-blocking 
vaccines [70] and are reviewed with a focus on endecto-
cides in the third paper of this thematic series [71].
Go/No‑Go criteria for pre‑clinical and early clinical 
development
As a reference point, the initially proposed parameters 
for transmission blocking vaccines included propor-
tion of oocyst reduction in a proportion of vaccinees for 
a defined period of time, i.e. >50% reduction in oocyst 
count in >50% of the vaccinees to advance from phase 
Ia to Ib and >80% reduction in oocyst count in >80% of 
the vaccinees for 9 months to advance from a Ib trial [64]. 
PATH’s original 2010 TPP for a transmission blocking 
vaccine proposed an 85% transmission-blocking efficacy 
as the efficacy target. Total oocyst prevalence has also 
been proposed as a more suitable reflection of infectiv-
ity [72]. Finally in laboratory populations, even modest 
reduction in vertebrate-to-insect transmission of 32% 
can eliminate Plasmodium infections [73].
For an ivermectin-based tool, early entomological Go/
No-Go criteria could include:
  • Cumulative 3-day mosquito mortality: reflecting a 
quick reduction in vector densities and with direct 
implication on an effect on human-to-mosquito 
transmission.
  • Cumulative 9-day mosquito mortality (before com-
pletion of sporogony): reflecting the reduction in 
infectious vectors.
  • The duration of the above effects.
  • Definitive proof of impact on human health will likely 
be required at later development stages given its 
importance for communities and policy makers.
The fact that sublethal concentrations can also reduce 
transmission by impairing flying and fertility should be 
taken into account as the total effect in the field could 
be higher than the expected effect just based on mortal-
ity. These could be assessed by evaluating the behaviour 
of vectors caught alive by using exit traps or equivalent 
methods. Decisions need to be made on (a) the appropri-
ate measurements of impact on human health, (b) meas-
urements that can help understand how the effect was 
reached (and what would need to be optimized in future 
studies) and that could in the future be considered as 
trial endpoints and (c) measurements that would lead to 
future hypotheses.
Conclusions
The clinical development of any ivermectin-based tool 
intended to reduce malaria transmission will require at 
least one pivotal cluster-randomized trial. For the plan-
ning of such a trial two key points must be considered, 
the eco-epidemiological scenario in which the trial will 
take place and the way ivermectin will be administered to 
the population. Mainly because of sample size, it is likely 
that running such a trial in an area of high seasonal trans-
mission would have the best value for early investment.
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